vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and Meridian Corp (MRBK). Click either name above to swap in a different company.

Meridian Corp is the larger business by last-quarter revenue ($34.2M vs $19.6M, roughly 1.8× STANDARD BIOTOOLS INC.). Meridian Corp runs the higher net margin — 428.0% vs -177.4%, a 605.4% gap on every dollar of revenue. On growth, Meridian Corp posted the faster year-over-year revenue change (5.1% vs -11.5%). Meridian Corp produced more free cash flow last quarter ($22.6M vs $-23.1M). Over the past eight quarters, Meridian Corp's revenue compounded faster (18.0% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Meridian Audio is a consumer audio and home theatre equipment manufacturer based in the United Kingdom. Bob Stuart and Allen Boothroyd founded the company in 1977 under the name Boothroyd-Stuart. In 1985 the company released a CD player under the brand name, Meridian. The company also created the lossless compression format Meridian Lossless Packing in 1998 and the lossy Master Quality Authenticated (MQA) format in 2014.

LAB vs MRBK — Head-to-Head

Bigger by revenue
MRBK
MRBK
1.8× larger
MRBK
$34.2M
$19.6M
LAB
Growing faster (revenue YoY)
MRBK
MRBK
+16.6% gap
MRBK
5.1%
-11.5%
LAB
Higher net margin
MRBK
MRBK
605.4% more per $
MRBK
428.0%
-177.4%
LAB
More free cash flow
MRBK
MRBK
$45.7M more FCF
MRBK
$22.6M
$-23.1M
LAB
Faster 2-yr revenue CAGR
MRBK
MRBK
Annualised
MRBK
18.0%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
MRBK
MRBK
Revenue
$19.6M
$34.2M
Net Profit
$-34.7M
$7.2M
Gross Margin
48.5%
Operating Margin
-168.5%
27.2%
Net Margin
-177.4%
428.0%
Revenue YoY
-11.5%
5.1%
Net Profit YoY
-28.8%
28.3%
EPS (diluted)
$-0.09
$0.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
MRBK
MRBK
Q4 25
$34.2M
Q3 25
$19.6M
$33.1M
Q2 25
$21.8M
$32.4M
Q1 25
$40.8M
$27.1M
Q4 24
$32.6M
Q3 24
$22.1M
$29.1M
Q2 24
$22.5M
$26.1M
Q1 24
$45.5M
$24.6M
Net Profit
LAB
LAB
MRBK
MRBK
Q4 25
$7.2M
Q3 25
$-34.7M
$6.7M
Q2 25
$-33.5M
$5.6M
Q1 25
$-26.0M
$2.4M
Q4 24
$5.6M
Q3 24
$-26.9M
$4.7M
Q2 24
$-45.7M
$3.3M
Q1 24
$-32.2M
$2.7M
Gross Margin
LAB
LAB
MRBK
MRBK
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
LAB
LAB
MRBK
MRBK
Q4 25
27.2%
Q3 25
-168.5%
26.2%
Q2 25
-118.1%
22.5%
Q1 25
-80.8%
11.6%
Q4 24
23.3%
Q3 24
-120.9%
21.5%
Q2 24
-134.5%
16.8%
Q1 24
-132.2%
14.4%
Net Margin
LAB
LAB
MRBK
MRBK
Q4 25
428.0%
Q3 25
-177.4%
20.1%
Q2 25
-153.7%
17.2%
Q1 25
-63.8%
8.9%
Q4 24
366.8%
Q3 24
-122.0%
16.3%
Q2 24
-203.3%
12.7%
Q1 24
-70.6%
10.9%
EPS (diluted)
LAB
LAB
MRBK
MRBK
Q4 25
$0.61
Q3 25
$-0.09
$0.58
Q2 25
$-0.09
$0.49
Q1 25
$-0.07
$0.21
Q4 24
$0.49
Q3 24
$-0.07
$0.42
Q2 24
$-0.12
$0.30
Q1 24
$-0.27
$0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
MRBK
MRBK
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$199.7M
Total Assets
$539.6M
$2.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
MRBK
MRBK
Q4 25
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q4 24
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Total Debt
LAB
LAB
MRBK
MRBK
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
MRBK
MRBK
Q4 25
$199.7M
Q3 25
$399.7M
$188.0M
Q2 25
$424.5M
$178.0M
Q1 25
$454.6M
$173.6M
Q4 24
$171.5M
Q3 24
$489.3M
$167.4M
Q2 24
$510.3M
$162.4M
Q1 24
$577.3M
$159.9M
Total Assets
LAB
LAB
MRBK
MRBK
Q4 25
$2.6B
Q3 25
$539.6M
$2.5B
Q2 25
$557.0M
$2.5B
Q1 25
$579.6M
$2.5B
Q4 24
$2.4B
Q3 24
$681.5M
$2.4B
Q2 24
$708.7M
$2.4B
Q1 24
$777.7M
$2.3B
Debt / Equity
LAB
LAB
MRBK
MRBK
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
MRBK
MRBK
Operating Cash FlowLast quarter
$-22.2M
$24.3M
Free Cash FlowOCF − Capex
$-23.1M
$22.6M
FCF MarginFCF / Revenue
-118.1%
65.9%
Capex IntensityCapex / Revenue
4.5%
5.1%
Cash ConversionOCF / Net Profit
3.38×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$51.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
MRBK
MRBK
Q4 25
$24.3M
Q3 25
$-22.2M
$24.4M
Q2 25
$-20.7M
$-12.0M
Q1 25
$-30.3M
$18.1M
Q4 24
$9.6M
Q3 24
$-27.9M
$31.2M
Q2 24
$-39.0M
$-19.2M
Q1 24
$-62.5M
$-1.7M
Free Cash Flow
LAB
LAB
MRBK
MRBK
Q4 25
$22.6M
Q3 25
$-23.1M
$24.0M
Q2 25
$-22.6M
$-12.7M
Q1 25
$-35.3M
$17.9M
Q4 24
$9.0M
Q3 24
$-30.1M
$29.5M
Q2 24
$-41.0M
$-19.3M
Q1 24
$-63.3M
$-3.6M
FCF Margin
LAB
LAB
MRBK
MRBK
Q4 25
65.9%
Q3 25
-118.1%
72.4%
Q2 25
-103.6%
-39.1%
Q1 25
-86.6%
65.9%
Q4 24
27.7%
Q3 24
-136.4%
101.4%
Q2 24
-182.2%
-73.8%
Q1 24
-138.9%
-14.7%
Capex Intensity
LAB
LAB
MRBK
MRBK
Q4 25
5.1%
Q3 25
4.5%
1.4%
Q2 25
8.7%
1.9%
Q1 25
12.4%
1.0%
Q4 24
1.7%
Q3 24
10.2%
6.0%
Q2 24
8.6%
0.2%
Q1 24
1.7%
7.8%
Cash Conversion
LAB
LAB
MRBK
MRBK
Q4 25
3.38×
Q3 25
3.66×
Q2 25
-2.15×
Q1 25
7.55×
Q4 24
1.71×
Q3 24
6.58×
Q2 24
-5.78×
Q1 24
-0.64×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

MRBK
MRBK

Segment breakdown not available.

Related Comparisons